Travere Therapeutics, Inc. - 8-K Filing
Travere Therapeutics held its 2026 Annual Meeting on May 19, where stockholders approved an increase in shares available under the 2018 Equity Incentive Plan by 3 million. Ten directors were elected with majority votes ranging from ~74% to ~89%. Stockholders also approved executive compensation (73.7M for) and ratified Ernst & Young as auditors (80.7M for). (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $TVTX